Recombinant human growth hormone (rHGH) for muscle enhancement in knee osteoarthritis: protocol for a pilot, randomised placebo-controlled trial.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The χ2 test will be used to determine whether the number of participants who made meaningful changes was different between groups.

Why It Was Studied

The management of active patients with symptomatic knee osteoarthritis (KnOA) who are too young for total knee arthroplasty poses a specific challenge to clinicians.

This study has been approved by the Sunnybrook Research Institute Research and Ethics Board (#6427) and received a no-objection letter from Health Canada Clinical Trials.

Who Took Part

The abstract describes 17 participants taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Participants are aged 18-60 with clinical and radiographic evidence of isolated degenerative arthritis of the knee (patellofemoral or tibiofemoral).

The secondary outcomes are knee extension strength, knee flexion strength, radiographic arthritis progression, thigh muscle circumference, MRI-measured quadriceps muscle volume and patient-reported outcome measures (Knee Osteoarthritis Outcome Score (KOOS), SF-20 and Tegner).

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

This is a single-centre, double-blind, randomised trial to pilot a future Phase III trial from 2025 to 2028.

The primary endpoint for these outcomes will be at 6 weeks.

The primary endpoint for these outcomes will be at 12 weeks, and the final endpoint will be 24 months, where final radiographic (X-ray) assessment will take place.The primary outcome of compliance will be a calculation of mean compliance between groups, which can be analysed as a t-test after the treatment period.

A two-sample, two-sided t-test will compare the clinical (secondary) outcome of greatest interest: knee extension strength at baseline versus week 6 compared between treatment groups.

Other secondary outcomes will be compared using a simple linear mixed-effects model.

What Was Measured

Topics PubMed links to this paper include Osteoarthritis, Knee, Human Growth Hormone, Muscle Strength, Recombinant Proteins, Pilot Projects, Quadriceps Muscle and Exercise Therapy.

Author keywords: Adult orthopaedics, Clinical Trial, Musculoskeletal disorders and SPORTS MEDICINE.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2026 (BMJ open), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.